文献速递银屑病与炎症性皮肤病

替拉珠单抗改善中重度斑块状银屑病高负担症状、睡眠障碍及生活质量:接近临床实践条件的研究

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-06-13

TRIBUTE 研究为开放标签 IV 期研究,纳入 177 例未使用过 IL-23/Th17 通路抑制剂的成人中重度斑块状银屑病患者,评估替拉珠单抗 100 mg 在接近临床实践条件下的疗效与健康相关生活质量。治疗 24 周后 PASI≤3、PASI 75、PASI 90 和 DLQI 0/1 的患者比例分别为 88.4%、92.5%、74.0% 和 70.4%,患者报告的瘙痒、疼痛、鳞屑、睡眠、工作效率及治疗满意度均改善,安全性良好且与 III 期试验一致。

要点

  • 替拉珠单抗 100 mg 治疗 24 周后 PASI 75 达 92.5%、PASI 90 达 74.0%。
  • DLQI 0/1 患者比例为 70.4%,Skindex-16 总分平均绝对变化为 -53.3。
  • 瘙痒、疼痛、鳞屑 NRS 及睡眠、工作效率均有显著改善,治疗满意度高。

核心结论

  • 在接近真实临床实践条件下,替拉珠单抗 100 mg 治疗 24 周对银屑病体征和健康相关生活质量显示出快速且高度的改善。
  • 患者报告的睡眠结局和工作效率改善、相关获益及高治疗满意度均得到体现,安全性良好且与 III 期试验一致。

研究设计与样本

  • TRIBUTE 研究为开放标签 IV 期研究,纳入 177 例未使用过 IL-23/Th17 通路抑制剂的成人中重度斑块状银屑病患者,评估替拉珠单抗 100 mg 在接近临床实践条件下的疗效与健康相关生活质量。
  • 主要疗效指标为银屑病面积严重程度指数(PASI),健康相关生活质量采用皮肤病生活质量指数(DLQI)和 Skindex-16 评估。
  • 患者报告结局还包括疼痛、瘙痒和鳞屑数字评定量表(NRS)、医学结局研究(MOS)睡眠量表、工作生产力和活动障碍(WPAI)、患者获益指数(PBI)及药物治疗满意度问卷(TSQM)。

主要发现

  • 治疗 24 周后,达到 PASI≤3、PASI 75、PASI 90 和 DLQI 0/1 的患者比例分别为 88.4%、92.5%、74.0% 和 70.4%。
  • Skindex-16 总分改善,平均绝对变化(MACB)[95%CI] 为 -53.3 [-58.1, -48.5]。
  • 瘙痒、疼痛和鳞屑 NRS 评分均显著改善,MACB [95%CI] 分别为 -5.7 [-6.1, -5.2]、-3.5 [-4.1, -3.0] 和 -5.7 [-6.2, -5.2]。
  • MOS 睡眠问题指数 II 的 MACB [95%CI] 为 -10.4 [-13.3, -7.4];WPAI 活动障碍、生产力损失、出勤主义和工作缺勤的 MACB [95%CI] 分别为 -36.4 [-42.6, -30.2]、-28.2 [-34.7, -21.7]、-27.0 [-32.9, -21.1] 和 -6.8 [-12.1, -1.5]。
  • 82.7% 的患者报告 PBI≥3,TSQM 全局评分均值(SD)较高,为 80.5(18.5);仅报告 1 例严重治疗中出现的不良事件,与替拉珠单抗无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tildrakizumab (TIL) is an interleukin (IL)-23p19 inhibitor for the treatment of moderate-to-severe plaque psoriasis with long-term efficacy and safety demonstrated in Phase III trials. Studies conducted in conditions closer to clinical practice are needed. OBJECTIVES: The TRIBUTE study (open-label, Phase IV) assessed the efficacy and impact on health-related quality of life (HRQoL) of TIL 100 mg in adult moderate-to-severe psoriasis patients (naïve to IL-23/Th17 pathway inhibitors) in conditions similar to clinical practice. METHODS: Key efficacy measure was Psoriasis Area Severity Index (PASI). HRQoL was evaluated using the Dermatology Life Quality Index (DLQI) and Skindex-16. Additional patient-reported outcomes included Pain-, Pruritus- and Scaling-Numerical Rating Scale (NRS), Medical Outcome Study (MOS)-Sleep, Work Productivity and Activity Impairment (WPAI), Patient Benefit Index (PBI) and Treatment Satisfaction Questionnaire for Medication (TSQM). RESULTS: One hundred and seventy-seven patients were enrolled (six patients did not complete the study). After 24 weeks, the proportion of patients achieving PASI scores ≤ 3, PASI 75, PASI 90 and DLQI 0/1 was 88.4%, 92.5%, 74.0% and 70.4%, respectively. Skindex-16 overall score improved (mean absolute change from baseline, MACB [95%CI]: -53.3 [-58.1, -48.5]). Significant benefits (MACB [95%CI]) were found on pruritus-, pain- and scaling-NRS scores (-5.7 [-6.1, -5.2], -3.5 [-4.1, -3.0] and -5.7 [-6.2, -5.2], respectively), MOS-Sleep (-10.4 [-13.3, -7.4] Sleep problems Index II) and WPAI (-36.4 [-42.6, -30.2] activity impairment, -28.2 [-34.7, -21.7] productivity loss, -27.0 [-32.9, -21.1] presenteeism and -6.8 [-12.1, -1.5] absenteeism). 82.7% of patients reported PBI ≥ 3 and the mean (SD) global TSQM score was high (80.5 [18.5]). Only one serious treatment-emergent adverse event was reported (not-related to TIL). CONCLUSIONS: TIL 100 mg treatment after 24 weeks in conditions close to real clinical practice showed a quick and high improvement in psoriasis signs and HRQoL. Patient reported improvements in sleep outcomes and work productivity, relevant benefits and high treatment satisfaction. The safety profile was favourable and consistent with Phase III trials.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Costanzo A, Llamas-Velasco M, Fabbrocini G, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023. PMID: 37246505. doi:10.1111/jdv.19229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。